Pieris Pharmaceuticals

Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. Pieris has established a diverse pipeline of Anticalin therapeutics for a number of different indications and has R&D collaborations with Roche, Daiichi Sankyo, the Sanofi Group and others. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.
Type
Public
HQ
Boston, US
Founded
2001
Size (employees)
38 (est)
Website
pieris.com
Pieris Pharmaceuticals was founded in 2001 and is headquartered in Boston, US

Pieris Pharmaceuticals Office Locations

Pieris Pharmaceuticals has an office in Boston
Boston, US (HQ)
255 State St

Pieris Pharmaceuticals Data and Metrics

Pieris Pharmaceuticals Financial Metrics

Pieris Pharmaceuticals's revenue was reported to be $1.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

1.3 m

Net income (Q1, 2017)

(8 m)

EBIT (Q1, 2017)

(8 m)

Market capitalization (25-Jul-2017)

242.9 m

Cash (31-Mar-2017)

55.2 m
Pieris Pharmaceuticals's current market capitalization is $242.9 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

5.4 m2.9 m5.8 m

Revenue growth, %

(45%)99%

R&D expense

(5.6 m)8.2 m19.7 m

General and administrative expense

(7 m)8.4 m8.9 m

Operating expense total

27416.6 m28.6 m

EBIT

(7.2 m)(13.7 m)(22.8 m)

EBIT margin, %

(134%)(467%)(390%)

Interest expense

(2.7 m)(184.6 k)2.3 k

Interest income

2.3 k

Pre tax profit

(9.8 m)(13.9 m)(22.6 m)

Income tax expense

18

Net Income

(9.8 m)(14.1 m)(22.8 m)
USDQ1, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

217.6 k160.2 k414.6 k1.2 m1.1 m785 k1.3 m

R&D expense

(1.5 m)(1.7 m)2.1 m3.7 m4.5 m4.6 m5.4 m

General and administrative expense

(2.4 m)(2 m)2.2 m2 m2.4 m2.3 m4 m

Operating expense total

(3.9 m)(3.7 m)4.3 m5.6 m6.9 m7 m9.3 m

EBIT

(13.9 k)(3.7 m)(3.5 m)(3.9 m)(4.4 m)(5.8 m)(6.2 m)(8 m)

EBIT margin, %

(1701%)(2206%)(936%)(351%)(540%)(787%)(596%)

Interest expense

(4.2 k)(53)(181.2 k)

Pre tax profit

(3.7 m)(3.5 m)(3.9 m)(4.2 m)(5.9 m)(6.2 m)(8 m)

Income tax expense

18

Net Income

(13.9 k)(3.7 m)(3.5 m)(3.9 m)(4.2 m)(5.9 m)(6.2 m)(8 m)
USDFY, 2014FY, 2015FY, 2016

Cash

18.5 m29.3 m29.4 m

Accounts Receivable

5.7 m99557.6 k

Inventories

2.3 m3.3 m

Current Assets

19.8 m31.7 m32.7 m

PP&E

2.1 m2.2 m2.3 m

Total Assets

21.9 m34 m35.1 m

Accounts Payable

1.3 m1.1 m2.4 m

Current Liabilities

3.5 m2.8 m8.4 m

Total Liabilities

9.8 m

Additional Paid-in Capital

84.6 m112.2 m129.3 m

Retained Earnings

(65.8 m)(79.9 m)(102.7 m)

Total Equity

18 m31.1 m25.2 m

Financial Leverage

1.2 x1.1 x1.4 x
USDQ1, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

13.2 m10 m32.3 m31.2 m40.4 m36.6 m55.2 m

Accounts Receivable

39 k

Current Assets

15 m12.6 m34.2 m34.9 m43.9 m41.1 m58.8 m

PP&E

1.8 m1.8 m1.9 m2.2 m2.4 m2.4 m3 m

Total Assets

16.8 m14.5 m36.2 m37.2 m46.5 m43.7 m61.9 m

Accounts Payable

6501.5 m2.1 m1.1 m1.7 m1.6 m4.5 m3.3 m

Current Liabilities

2.3 m3 m2.2 m6.5 m6.4 m10 m11.4 m

Additional Paid-in Capital

85.2 m85.5 m111.7 m112.6 m128.5 m128.9 m130.1 m

Retained Earnings

(29.9 k)(69.5 m)(73 m)(77 m)(84 m)(89.9 m)(96.1 m)(110.7 m)

Total Equity

14.2 m11.1 m33.7 m27.2 m37.3 m31.5 m18 m

Financial Leverage

1.2 x1.3 x1.1 x1.4 x1.2 x1.4 x3.4 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(9.8 m)(14.1 m)(22.8 m)

Depreciation and Amortization

367 k307.9 k361.4 k

Accounts Receivable

465.4 k465.4 k(58.7 k)

Inventories

4 k(136.3 k)127.5 k

Accounts Payable

1.1 m(90.9 k)1.4 m

Cash From Operating Activities

(274)(12.7 m)(14.4 m)

Purchases of PP&E

(267.4 k)(620.7 k)(580.6 k)

Cash From Investing Activities

(267.4 k)(620.7 k)(559.7 k)

Long-term Borrowings

(181.5 k)(1.2 m)(1.2 m)

Cash From Financing Activities

20.3 m24.6 m15.2 m

Interest Paid

71.8 k206.3 k206.3 k

Income Taxes Paid

47.9 k203.9 k162 k
USDQ1, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.9 k)(3.7 m)(3.5 m)(3.9 m)(4.2 m)(5.9 m)(6.2 m)(8 m)

Accounts Receivable

17.4 k70.3 k39 k

Accounts Payable

1.5 m2.1 m1.1 m1.7 m1.6 m4.5 m3.3 m

Cash From Operating Activities

(13.9 k)

Cash From Financing Activities

3 k
USDY, 2017

Revenue/Employee

35.4 k

Financial Leverage

3.4 x

Pieris Pharmaceuticals Market Value History

Pieris Pharmaceuticals News and Updates

Pieris Pharmaceuticals Company Life and Culture

You may also be interested in